Related Experiment Video
Updated: Jan 11, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Does Health-Based Prospective Risk Adjustment Adequately Compensate for Individuals Diagnosed With a New Chronic
Michel Oskam1, Richard C van Kleef1, René C J A van Vliet1
1Erasmus School of Health Policy & Management, Erasmus Centre for Health Economics Rotterdam, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Abstract:
Many regulated health insurance markets use prospective risk adjustment (RA) to mitigate risk selection incentives for insurers. However, prospective RA might underpay insurers for people diagnosed with a new chronic disease. By tracking spending and RA payments over the period t-2 to t+2 for individuals diagnosed with a new chronic disease in year t, we find a substantial payment gap in year t and, to a lesser extent, in prior and/or subsequent years. The extent to which these gaps stimulate selection incentives for insurers depends on the possibilities for insurers to distort consumers' choice of insurance products. Possibilities which-in turn-depend on whether and when consumers respond to the onset of the chronic disease when choosing an insurance product. By analyzing "insurer switching" in the period t-2 to t+2 we find that-on average-people first diagnosed with a chronic disease are more likely to switch insurer than others.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
Relative Risk
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Bias in Epidemiological Studies

